AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34293489 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 IgG and IgM
Number of subjects: 3142
Study 34293489 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall seroprevalence
Number of subjects: 3142
Study 34293489 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroprevalence by LGA
Number of subjects: 3142
Study 34293489 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian Adjustments
Number of subjects: 3142
Study 32481557 — intervention group
Group type: EXPERIMENTAL
Intervention: Biscuit with a beverage of powdered mulberry leaves
Number of subjects: 18
Study 32481557 — intervention group
Group type: EXPERIMENTAL
Intervention: Biscuit with a beverage of powdered barley leaves
Number of subjects: 18
Study 32481557 — intervention group
Group type: EXPERIMENTAL
Intervention: Biscuit
Number of subjects: 18
Study 32481557 — intervention group
Group type: COMPARATOR
Intervention: No biscuits
Number of subjects: 18
Study 35653934 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT; N = 86)
Number of subjects: 130
Study 35653934 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific education/support (EDU; N = 44)
Number of subjects: 130
Study 34124928 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTV
Number of subjects: 725
Study 34124928 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 725
Study 33693863 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP-targeted monoclonal antibodies (CGRP-targeted mAbs) as add-on therapy to onabotulinumtoxinA
Number of subjects: 153
Study 33693863 — intervention group
Group type: COMPARATOR
Intervention: OnabotulinumtoxinA
Number of subjects: 153
Study 34905302 — intervention group
Group type: EXPERIMENTAL
Intervention: ER-tacrolimus
Number of subjects: 92
Study 34905302 — intervention group
Group type: EXPERIMENTAL
Intervention: LCP-tacrolimus
Number of subjects: 92
Study 34905302 — intervention group
Group type: COMPARATOR
Intervention: IR-tacrolimus
Number of subjects: 92
Study 32881699 — intervention group
Group type: EXPERIMENTAL
Intervention: Visibility graph features derived from heart rate variability (HRV) data
Number of subjects: 49
Study 32881699 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional HRV features
Number of subjects: 49
Study 32881699 — intervention group
Group type: COMPARATOR
Intervention: Control group (infants who did not receive antibiotics)
Number of subjects: 49
Study 34176862 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical aortic valve replacement (AVR)
Number of subjects: 0
Study 34176862 — intervention group
Group type: COMPARATOR
Intervention: Watchful observation
Number of subjects: 0
Study 34189447 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg twice daily for 14 days
Number of subjects: 158
Study 34189447 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 158
Study 34743554 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg daily)
Number of subjects: 3112
Study 34743554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3112
Study 33670535 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle loss phenotype in patients >65 years old with cirrhosis
Number of subjects: 29018
Study 33670535 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle loss phenotype in patients ≤50 years old with cirrhosis
Number of subjects: 29018
Study 33670535 — intervention group
Group type: COMPARATOR
Intervention: Muscle loss phenotype in both GMP and inpatients with cirrhosis aged 51–65 years and >65 years
Number of subjects: 29018
Study 33670535 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-home discharges (nursing, skilled, long-term care) in patients with cirrhosis with muscle loss phenotype
Number of subjects: 29018
Study 33298105 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate, low-fat (HCLF) diet
Number of subjects: 8
Study 33298105 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate, high-fat (LCHF) diet
Number of subjects: 8
Study 34088237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate partner violence training program based on the theory of planned behavior
Number of subjects: 99
Study 34088237 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 99
Study 32170355 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical co-delivery of platelet rich fibrin (PRF) and tranexamic acid (TA)
Number of subjects: 80
Study 32170355 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (combined intravenous and topical TA)
Number of subjects: 80
Study 36329307 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure management (target < 130 mm Hg)
Number of subjects: 600
Study 36329307 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure management (target < 180 mm Hg)
Number of subjects: 600
Study 36329307 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure management
Number of subjects: 600
Study 36329307 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure management
Number of subjects: 600
Study 32462642 — intervention group
Group type: EXPERIMENTAL
Intervention: TKA design with baseplates size 3 or smaller
Number of subjects: 14966
Study 32462642 — intervention group
Group type: EXPERIMENTAL
Intervention: TKA design with polyethylene insert thickness of 13 mm or larger
Number of subjects: 14966
Study 32462642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative tibia fractures treatment
Number of subjects: 14966
Study 32462642 — intervention group
Group type: COMPARATOR
Intervention: Control group of 75 patients (80 knees)
Number of subjects: 14966
Study 32160368 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dimethyl sulfoxide (DMSO) 50% solution
Number of subjects: 18
Study 32160368 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.5% cream
Number of subjects: 18
Study 36186784 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous injection of vitamin C (200 mg/kg/24 h) for 4 days
Number of subjects: 620
Study 36186784 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) for 4 days
Number of subjects: 620
Study 32041717 — intervention group
Group type: EXPERIMENTAL
Intervention: Nacubactam 50 to 8,000 mg single ascending doses
Number of subjects: 0
Study 32041717 — intervention group
Group type: EXPERIMENTAL
Intervention: Nacubactam 1,000 to 4,000 mg multiple ascending doses every 8 hours for up to 7 days
Number of subjects: 0
Study 32041717 — intervention group
Group type: EXPERIMENTAL
Intervention: Nacubactam 2,000 mg plus meropenem 2,000 mg every 8 hours for 6 days after a 3-day lead-in period
Number of subjects: 0
Study 32041717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35055783 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic initiation technique (RIT)
Number of subjects: 61
Study 35055783 — intervention group
Group type: COMPARATOR
Intervention: Teaching correct breathing patterns
Number of subjects: 61
Study 33887662 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS with physical therapy (PT)
Number of subjects: 20
Study 33887662 — intervention group
Group type: EXPERIMENTAL
Intervention: Real cTBS with physical therapy (PT)
Number of subjects: 20
Study 33887662 — intervention group
Group type: COMPARATOR
Intervention: Sham cTBS with physical therapy (PT)
Number of subjects: 20
Study 35973878 — intervention group
Group type: EXPERIMENTAL
Intervention: Illuminated musical mobile
Number of subjects: 124
Study 35973878 — intervention group
Group type: COMPARATOR
Intervention: Routine sleep routines
Number of subjects: 124
Study 33394989 — intervention group
Group type: EXPERIMENTAL
Intervention: L-T mode at output power of 60 W and 84 W
Number of subjects: 60
Study 33394989 — intervention group
Group type: COMPARATOR
Intervention: L mode
Number of subjects: 60
Study 33394989 — intervention group
Group type: EXPERIMENTAL
Intervention: L-T mode
Number of subjects: 60
Study 35366419 — intervention group
Group type: EXPERIMENTAL
Intervention: AJM300 (960 mg) administered orally, three times daily for 8 weeks
Number of subjects: 203
Study 35366419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 33492021 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Bridge (intensive case management intervention)
Number of subjects: 100
Study 33492021 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 100
Study 32315435 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors (PRGF)
Number of subjects: 40
Study 32315435 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural bovine bone mineral covered with resorbable native collagen membrane (BBM/CM)
Number of subjects: 40
Study 32315435 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze‐dried bone allograft covered with resorbable native collagen membrane (FDBA/CM)
Number of subjects: 40
Study 32315435 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous healing (control)
Number of subjects: 40
Study 34549819 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Antioxidants (AO) 2.0%
Number of subjects: 20
Study 34549819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 32078089 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct costs of mental health services and indirect costs from missed school and work.
Number of subjects: 209
Study 32078089 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher anxiety and depression severity.
Number of subjects: 209
Study 34809923 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal femoral nailing in the lateral position without a traction table (Group 1)
Number of subjects: 80
Study 34809923 — intervention group
Group type: COMPARATOR
Intervention: Proximal femoral nailing in the supine position with a traction table (Group 2)
Number of subjects: 80
Study 34463344 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated web-based intervention for PTSD symptoms and hazardous drinking (n = 81)
Number of subjects: 162
Study 34463344 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 162
Study 33745292 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 80
Study 33745292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 33352771 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet enriched in extra-virgin olive oil
Number of subjects: 6772
Study 33352771 — intervention group
Group type: COMPARATOR
Intervention: Low-fat control intervention
Number of subjects: 6772
Study 33352771 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Number of subjects: 6772
Study 36267895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-pemetrexed with intercalated erlotinib (CPE)
Number of subjects: 22
Study 36267895 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib monotherapy
Number of subjects: 22
Study 34247613 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress urinary incontinence (stress UI)
Number of subjects: 4051
Study 34247613 — intervention group
Group type: EXPERIMENTAL
Intervention: Urge urinary incontinence (urge UI)
Number of subjects: 4051
Study 34247613 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary incontinence without stress or urge
Number of subjects: 4051
Study 34247613 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers for healthcare-seeking for stress UI
Number of subjects: 4051
Study 34247613 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers for healthcare-seeking for urge UI
Number of subjects: 4051
Study 34247613 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers for healthcare-seeking for UI without stress or urge
Number of subjects: 4051
Study 34247613 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of educational level with barriers
Number of subjects: 4051
Study 32301681 — intervention group
Group type: EXPERIMENTAL
Intervention: LIST
Number of subjects: 2
Study 32301681 — intervention group
Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 2
Study 33707393 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Amrita Meditation® technique (IAM®)
Number of subjects: 30
Study 33707393 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 35337223 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS combined with SLT
Number of subjects: 67
Study 35337223 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation combined with SLT
Number of subjects: 67
Study 34666379 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg twice daily) starting from 14 to 20 weeks' gestation until delivery
Number of subjects: 80
Study 34666379 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg twice daily)
Number of subjects: 80
Study 34666379 — intervention group
Group type: COMPARATOR
Intervention: Low dose aspirin (80 mg/day) and calcium (1 g/day)
Number of subjects: 80
Study 35429974 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic model based on intra-nodular and peri-nodular features
Number of subjects: 1018
Study 35429974 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-nodular radiomic features
Number of subjects: 1018
Study 35429974 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on lobulation sign and radiomic features
Number of subjects: 1018
Study 35429974 — intervention group
Group type: COMPARATOR
Intervention: Clinical-semantic model
Number of subjects: 1018
Study 32147827 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic tablets (T(+), T(-))
Number of subjects: 80
Study 32147827 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (C(+), C(-))
Number of subjects: 80
Study 32147827 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic tablets (T(-))
Number of subjects: 80
Study 36129998 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofersen (100 mg, 8 doses over 24 weeks)
Number of subjects: 108
Study 36129998 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofersen (100 mg, early-start cohort)
Number of subjects: 108
Study 36129998 — intervention group
Group type: COMPARATOR
Intervention: Placebo (delayed-start cohort)
Number of subjects: 108
Study 36129998 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofersen
Number of subjects: 108
Study 34127040 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized nasal intermittent positive pressure ventilation (SNIPPV)
Number of subjects: 30
Study 34127040 — intervention group
Group type: COMPARATOR
Intervention: Non-synchronized nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 30
Study 32614534 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-light wheelchair
Number of subjects: 18
Study 32614534 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight wheelchair
Number of subjects: 18
Study 32614534 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard wheelchair
Number of subjects: 18
Study 35089507 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 160
Study 33402094 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty Index (FI30) assessment
Number of subjects: 400
Study 33402094 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 70 years and above
Number of subjects: 400
Study 33402094 — intervention group
Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 400
Study 33402094 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher family income (Income>$473.3)
Number of subjects: 400
Study 32965495 — intervention group
Group type: EXPERIMENTAL
Intervention: VP-102
Number of subjects: 528
Study 32965495 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 528
Study 35799272 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg three times daily
Number of subjects: 21
Study 35799272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 34511464 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivortin aspartate (40 ml daily for 14 days)
Number of subjects: 0
Study 34511464 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3% glucose solution, identical dosage and duration)
Number of subjects: 0
Study 32725680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone combined with metronidazole
Number of subjects: 120
Study 32725680 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 120
Study 32725680 — intervention group
Group type: COMPARATOR
Intervention: Normal group (no treatment)
Number of subjects: 120
Study 35017255 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Stratified Telehealth
Number of subjects: 60
Study 35017255 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 33831037 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue Group
Number of subjects: 40
Study 33831037 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 40
Study 36441705 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visiting (NHV) - 25 nurse home visits (mean 23.2 home visits [SD 7.4, range 1-43] received) of 60-90 minutes, commencing antenatally and continuing until children's second birthdays.
Number of subjects: 722
Study 36441705 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 722
Study 34121413 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI6012 (intravenous doses of 24, 80, 240, and 800 mg)
Number of subjects: 48
Study 34121413 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI6012 (subcutaneous doses of 80 and 600 mg)
Number of subjects: 48
Study 34121413 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI6012 (intravenous doses)
Number of subjects: 48
Study 34121413 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI6012 (subcutaneous doses)
Number of subjects: 48
Study 34121413 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI6012 (all doses)
Number of subjects: 48
Study 34121413 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI6012 (intravenous doses of 80, 240, and 800 mg)
Number of subjects: 48
Study 34121413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 32202313 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtheoretical model-based exercise program (24 weeks)
Number of subjects: 189
Study 32202313 — intervention group
Group type: COMPARATOR
Intervention: Non-theory-based exercise program
Number of subjects: 189
Study 35900607 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 µg sc daily for 48 weeks)
Number of subjects: 587
Study 35900607 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (70 mg oral weekly for 48 weeks)
Number of subjects: 587
Study 35900607 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 587
Study 35900607 — intervention group
Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 587
Study 33245751 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-induction patient-reported outcomes (PROs) of abdominal pain (AP) and stool frequency (SF)
Number of subjects: 220
Study 33245751 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-induction patient-reported outcomes (PROs) of stool frequency (SF)
Number of subjects: 220
Study 32713213 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent incentive-based strategy
Number of subjects: 512
Study 32713213 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-value noncash incentives linked to goal setting
Number of subjects: 512
Study 32924586 — intervention group
Group type: EXPERIMENTAL
Intervention: IT + DL
Number of subjects: 150
Study 32924586 — intervention group
Group type: EXPERIMENTAL
Intervention: IT + IF
Number of subjects: 150
Study 32924586 — intervention group
Group type: EXPERIMENTAL
Intervention: IT
Number of subjects: 150
Study 32924586 — intervention group
Group type: COMPARATOR
Intervention: ITsham
Number of subjects: 150
Study 32924586 — intervention group
Group type: COMPARATOR
Intervention: NT
Number of subjects: 150
Study 35589493 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind orotracheal intubation (group B)
Number of subjects: 24
Study 35589493 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic-guided orotracheal intubation (group E)
Number of subjects: 24
Study 35589493 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (B and E)
Number of subjects: 24
Study 33109390 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 2 + 1 (received pneumococcal conjugate vaccine 13 valent at 2, 4 and 12 months)
Number of subjects: 0
Study 33109390 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 1 + 1 (received reduced schedule at 3 and 12 months)
Number of subjects: 0
Study 33109390 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine
Number of subjects: 0
Study 33924514 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula enriched with 0.8 g/dL of Orafti®Synergy1
Number of subjects: 160
Study 33924514 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented control formula
Number of subjects: 160
Study 36239137 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural weight management programmes (BWMPs)
Number of subjects: 150000
Study 33289835 — intervention group
Group type: EXPERIMENTAL
Intervention: MARPE
Number of subjects: 60
Study 33289835 — intervention group
Group type: COMPARATOR
Intervention: Hyrax
Number of subjects: 60
Study 32656692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received a preconception risk assessment, tailored health education, and referral for clinical follow‐up as needed.
Number of subjects: 40
Study 32656692 — intervention group
Group type: COMPARATOR
Intervention: Control group received standard care.
Number of subjects: 40
Study 35124281 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding messaging
Number of subjects: 997
Study 35124281 — intervention group
Group type: COMPARATOR
Intervention: Safe sleep messaging
Number of subjects: 997
Study 33576030 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 56
Study 33576030 — intervention group
Group type: COMPARATOR
Intervention: 2DRT
Number of subjects: 56
Study 33221142 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-level alcohol prevention intervention including sobriety checkpoints, saturation patrols, and undercover operations.
Number of subjects: 24
Study 33221142 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 24